Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that it is scheduled to present this week at the Jefferies Second Annual Healthcare Conference on Wednesday, June 25, 2008, at 2:30 p.m. (EDT) in New York City. The event will be webcast live and will be available on the Company’s website or by visiting http://www.wsw.com/webcast/jeff26/abpi. An archived edition of the presentation will be available following the event.

Based on imminent reports of milestones expected from Accentia’s majority owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), Steven Arikian, M.D. will focus his presentation on BiovaxID®, Biovest’s anti-cancer vaccine targeting non-Hodgkin’s lymphoma. Dr. Arikian serves as President and Chief Operating Officer, Biopharmaceutical Products & Services, of Accentia and as Chairman and CEO of Biovest.

If qualified investors are interested in meeting with Dr. Arikian at the Jefferies Healthcare Conference, please contact Douglas Calder at 813-864-2558 or at dwcalder@accentia.net.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. (Nasdaq:ABPI) is committed to building significant value for its stockholders through the commercialization of patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The Company generated more than $18 million in revenues in fiscal-year 2007, primarily based on sales of its marketed specialty pharmaceutical products and its analytical consulting business serving biopharmaceutical clients.

Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID®, a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin’s lymphoma; Revimmune™, a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase™, a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.

Accentia’s interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc. (OTCBB:BVTI), and Accentia also maintains a royalty interest in Biovest’s biologic products.